In Australia, over 3.7 million prescriptions for antithrombotic therapy with antiplatelet and anticoagulant drugs were dispensed in 2013 to prevent and treat the growing age-related incidence of venous and arterial thromboembolism 1 . The prescription rate is rising at 7% per annum, thus there is an increasing number of patients requiring perioperative advice for antithrombotic management. When these patients on antithrombotic therapy undergo surgery or neuraxial blockade, there is a real dilemma for the anaesthetist to balance the risk of thromboembolism during antithrombotic cessation against the potential of unnecessary haemorrhage or harmful consequence during the intervention. Guidelines such as those produced by the American College of Chest Physicians 2 and others are widely quoted and regularly updated to inform clinical decisions based on the best available evidence for a personalised approach for individual clinical management and avoidance of adverse clinical outcomes 3, 4 . Such guidelines recommend the minimum time period prior to or after intervention to cease or recommence antithrombotic drugs respectively, and only in special circumstances is laboratory measurement of the antithrombotic effect used in their recommendations.
In this issue of Anaesthesia and Intensive Care a correspondence by Ortigueira et al describes the delay of epidural catheter insertion in a parturient woman due to the observation of unexpectedly elevated anti-Xa activity resulting from low molecular weight heparin (LMWH) prophylaxis 5 . The situation raises specific issues regarding laboratory measurement of antithrombotic drug activity and/or plasma levels and their utility for clinical practice, especially in certain situations such as those with unacceptable bleeding consequences (neurosurgery, epidural insertion), in special clinical scenarios (pregnancy, obesity, renal impairment or on combined antiplatelet and anticoagulant therapy) or in patients treated with the new direct oral anticoagulants (DOACs) such as dabigatran (direct thrombin inhibitor), or rivaroxaban and apixaban (direct factor Xa inhibitors).
The most widely used anticoagulant drug is warfarin which is regularly monitored and adjusted by the International Normalized Ratio (INR) 6 . The therapeutic range for warfarin is well established at INR values between 2.0 and 3.0 for most indications and the general recommendation of cessation five days before surgery is based on the pharmacokinetic profile (mean half-life of 40 hours) 2,7 . Most patients (>90%) obtain an acceptable INR of <1.5 after stopping warfarin five days prior to surgery 8 . In the minority of patients who continue to have an INR of >1.5, further intervention with vitamin K, prothrombin concentrate or fresh frozen plasma may hasten its correction, depending on the urgency and indication for intervention. The INR is widely accepted as a surrogate outcome measure for predicting effective surgical haemostasis.
In patients treated with intravenous unfractionated heparin (UFH), the dose is usually adjusted to maintain the activated partial thromboplastin time (aPTT) at an intensity equivalent to an anti-Xa activity of 0.35 to 0.7 IU/ml. Similar to monitoring of INR in patients treated with warfarin, monitoring the aPTT serves as a reliable surrogate for the activity of UFH. An accepted therapeutic range for UFH corresponds to a 1.5 to 2.5 fold prolongation of the aPTT over the reference value 9 . Unfractionated heparin has a short half-life (30 minutes) and is immediately reversed by protamine sulfate; cessation of an infusion four to six hours before surgery is the widely accepted guideline for achieving haemostasis without necessitating laboratory testing 2, 9 . Extensive clinical experience and consensus opinion, rather than randomised controlled clinical trials, have guided periprocedural practice with both warfarin and unfractionated heparin.
In contrast to warfarin and unfractionated heparin, LMWHs produce a more predictable anticoagulant response; as such, they do not usually require laboratory monitoring. Therapeutic doses are scaled to body weight and are administered subcutaneously, once or twice daily. LMWHs are excreted by the Anaesth Intensive Care 2014; 42: 555-557 Editorial Does preoperative laboratory monitoring of antithrombotic therapy avoid adverse outcomes in patients undergoing surgery or regional anaesthesia? kidneys and their anticoagulant effects are only partially reversed with administration of protamine sulfate. The half-life of LMWH (three to six hours) varies with different preparations, as does the anti-Xa to anti-IIa activity ratio of individual agents 9 .
Pregnancy and epidural insertion are both clinical situations that rely on international expert and consensus recommendations to determine the optimal time between the last dose of an anticoagulant and the intervention rather than the clinician relying on a laboratory measurement. Clinicians in real life are conservative; in one study of prophylactic enoxaparin in pregnancy, the mean time after cessation before an epidural was performed was 54 hours, which compares generously to guideline recommendations of 24 hours 3 . The current case report uses intermediatelevel, twice daily dosing of LMWH-for which there is little data for safety with an epidural, which may have led to the assessment of anti-Xa levels. At 24 hours, the anti-Xa level was 0.29 IU/ml which was above the locally accepted level for haemostasis (0.20 IU/ml). Recent antenatal pharmacokinetic data with LMWH supports the case observation of increased trough anti-Xa activity with pregnancy that may lead to modification of future international guidelines 10 .
The challenge for clinicians is that there is no widely validated anti-Xa activity threshold for interventional haemostasis in the context of LMWH that is predictive for haemorrhage. The lack of association of anti-Xa levels <0.2 IU/ml with haemorrhage in patients with renal failure 11 is widely quoted but not prospectively studied in the perioperative or obstetric setting, creating much uncertainty about whether this cut-off can be extrapolated to other clinical scenarios. Many factors are involved that can increase haemorrhage, including surgical or interventional technique, use of antiplatelet agents and medical conditions causing coagulopathy or thrombocytopenia. It is likely there is an incremental increase in risk of haemorrhage with increasing anti-Xa activity. Measurement of plasma levels of the DOACs has recently been validated and is increasingly used in clinical practice because of the three-to five-fold individual variation in drug concentrations. This variation can have clinically significant implications, despite their wide therapeutic range 12 . Similar issues observed with LMWH are now arising in patients treated with DOACs-should expert opinion of stopping DOACs a certain time before surgery/intervention be accepted depending on the clinical judgement of the risk of bleeding and thromboembolism, or should we measure anticoagulant levels to guide practice?
Issues have now arisen about the definition of a safe haemostatic level for each DOAC (e.g. < 30 to 50 ng/ml for dabigatran), speed of the assay result turnaround time especially in emergency situations, what haemostatic intervention should be given if the result is deemed to be excessive for emergency surgery (e.g. Prothrombinex VF ® , FEIBA ® , recombinant activated factor VIIa, tranexamic acid), and the cost of laboratory testing; the logistic difficulties in designing studies to answer these questions are all potential hurdles to consider 12 . There is no doubt that in special circumstances, especially in patients with renal impairment or who are at high risk for unacceptable surgical haemorrhage, that DOAC therapeutic drug monitoring will be helpful in making clinical decisions based on risk/benefit assessment 13 . Further, carefully designed studies will assist in answering the question of whether laboratory testing will be helpful or misleading in guiding perioperative clinical decisions with the new and older anticoagulants. Until then, clinicians may err on the side of caution for DOACs and LMWH if there is doubt about residual drug effects or if monitoring is not possible. For example, rather than wait the standard three to four half-lives they should consider waiting longer, especially in patients with renal impairment and those with other risk factors or concerns for abnormal bleeding.
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